Phosphorylation of SMAD3 in immune cells predicts survival of patients with early stage non-small cell lung cancer.
Sebastian MarwitzCarmen Ballesteros-MerinoShawn M JensenMartin ReckChristian KuglerSven PernerDaniel DrömannTorsten GoldmannBernard A FoxPublished in: Journal for immunotherapy of cancer (2021)
TGFB pathway activation of local immune cells within the tumor microenvironment impacts survival of early stage lung cancer. This might benefit patients not eligible for targeted therapies or immune checkpoint therapy as a therapeutic option to re-activate the local immune response.
Keyphrases
- early stage
- immune response
- end stage renal disease
- ejection fraction
- newly diagnosed
- prognostic factors
- peritoneal dialysis
- sentinel lymph node
- free survival
- epithelial mesenchymal transition
- stem cells
- squamous cell carcinoma
- dendritic cells
- patient reported outcomes
- mesenchymal stem cells
- lymph node
- cell therapy
- patient reported